Many preclinical studies have been described with QDs, for instance targeting epidermal growth factor receptor (EGFR) with multifunctional siRNA-QD constructs for selectively inhibiting the expression of EGFRvariant III in target human U87 glioblastoma cells [92]. The gene discussed is EGFR; the disease is glioblastoma.